CIBA VISION BUYING IOLAB PHARMACEUTICAL BUSINESS FOR $300 MIL.
This article was originally published in The Tan Sheet
Executive Summary
CIBA VISION BUYING IOLAB PHARMACEUTICAL BUSINESS FOR $300 MIL. under a definitive agreement between the Ciba-Geigy and Johnson & Johnson subsidiaries announced Aug. 9. The transaction, which includes a cash payment to Johnson & Johnson upon closing and "future financial considerations," encompasses Iolab's entire pharmaceutical line but excludes other portions of Iolab's ophthalmic business, including intraocular lenses, microsurgical equipment and viscoelastic materials.